The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has granted orphan drug designation to zenocutuzumab-zbco for the therapy of adults with superior unresectable...
The U.S. Meals and Drug Administration (FDA) has authorized an replace to the prescribing info for Yescarta (axicabtagene ciloleucel), eradicating earlier limitations...
